查詢結果分析
相關文獻
- Efficacy and Dose Adjustment of Oral Desmopressin (DDAVP) in Patients with Central Diabetes Insipidus
- Lung Cancer in Pregnancy: Report of Two Cases
- Ifosfamide-Based Chemotherapy for Previously Treated Lung Cancer Patients
- 化學防癌與肺癌
- 非小細胞肺癌術前輔助性化學治療的經驗
- Outcome of Patients with Lung Cancer Treated with Mechanical Ventilation for Respiratory Failure
- 不吸菸婦女肺癌研究
- Docetaxel (Taxotere)--治療乳癌與肺癌的新藥
- The Evolution of the Diagnosis and Understanding of Lung Cancer Pathology: Living Through an Epoch
- Delayed Diagnosis of Lung Cancer in Taichung Veterans General Hospital
頁籤選單縮合
題 名 | Efficacy and Dose Adjustment of Oral Desmopressin (DDAVP) in Patients with Central Diabetes Insipidus=口服dDAVP治療中樞性尿崩症患者的劑量與效果 |
---|---|
作 者 | 許杏如; 黃建鐘; 高雅慧; 劉信良; 宋俊明; | 書刊名 | 臺灣腎臟醫學會雜誌 |
卷 期 | 16:3 2002.09[民91.09] |
頁 次 | 頁128-132+143 |
分類號 | 415.8 |
關鍵詞 | 中樞性尿崩症; 肺癌; 水份剝奪試驗; dDAVP Desmopressin錠劑; Central diabetes insipidus; CDI; Water deprivation test; Desmopressin tablet; dDAVP; |
語 文 | 英文(English) |
中文摘要 | 中樞性尿崩症(central diabetes insipidus, CDI)是因為缺乏抗尿激素(ADH)-即一罕見的疾病,它會導致體內水份無法保留而現多尿頻渴之臨床症狀。Desmopressin(1-desamino-8-D-arginine-vasopressin, dDAVP)是一類似ADH的合成物質,在臨床使用上,已超過二十年。目八是治療中樞性尿症最有效的藥物,而經由鼻腔投與每天二至三次是典型的給藥方式。近來,證實dDAVP經由口服投與,也具有抗利尿活性。我們提出兩個中樞性尿症病例報告,一為肺癌轉移引起,另一為原發性。給予口服的dDAVP錠劑並經過適當的調整劑後,它可安全有效的控制中樞性尿崩症病患的水份平衡。 |
英文摘要 | Central diabetes insipidus (CDI) is an uncommon disease caused by the deficiency of antidiuretic hormone (ADH), i.e. vasopressin. Deficiency of ADH leads to a failure to conserve water and results in polyuria and polydipsia. Desmopressin (1-desamino-8-Darginine vasopressin, dDAVP), a synthetic analogue of vasopressin, has been utilized for over 20 years, it is the most effective drug for the management of CDI and is adminosered typically by intranasal route one to three times daily. Recently, dDAVP was proven to be effective when given orally. The experience of treating CDI with oral dDAVP is limited in Taiwan. We hereby reported two cases of CDI, one was caused by metastatic lung cancer and the other was idiopathic. These two cases responded to administration of oral dDAVP without notable side-effects. In this report, we shared our experience in dosage adjustment of dDAVP that was critical for successful treatment. The pharmacokinetic characteristics of oral dDAVP were also discussed in this report. |
本系統中英文摘要資訊取自各篇刊載內容。